medigraphic.com
ISSN 1561-3011 (Electronic)

2020, Number 3

<< Back Next >>

Rev Cubana Invest Bioméd 2020; 39 (3)

Pathogenesis of neurological manifestations associated to SARS-CoV-2

Padrón-González AA, Dorta-Contreras AJ

Language: Spanish
References: 43
Page: 1-16
PDF size: 244.82 Kb.


ABSTRACT

Introduction: Coronaviruses infect humans and may cause neurological manifestations in susceptible individuals.
Objective: Describe the pathogenesis of neurological manifestations in patients with COVID-19.
Search strategy and selection criteria: A review was conducted of national and international updated bibliography. The search was carried out in Google Scholar and open access papers were consulted in the databases PubMed and SciELO from January 2014 to 6 May 2020. A total 51 papers (6 in Spanish and 45 in English) and a book on neuroimmunology were selected. The search terms used were “COVID-19”, “coronavirus”, “SARS-CoV-2”, “neurological manifestations”, “nervous system” and “pathogenesis”, in compliance with the Health Sciences Descriptors (DeCS).
Data analysis and integration: SARS-CoV-2 enters the nervous system by lymphatic, hematogenous, transynaptic, retrograde routes, by local dissemination through the ethmoid, or by dysfunction of the hematoencephalic barrier. Pathogenesis may be due to direct action by the virus or immunomediated. During the COVID-19 pandemic patients have been reported with central, peripheral and musculoskeletal neurological manifestations. The most common symptoms are taste and smell disorders, headache, myalgia and dizziness. Meningitis, encephalitis, Guillain-Barré syndrome, stroke and encephalopathies have been reported in severe forms of the disease.
Conclusions: SARS-CoV-2 may affect the central and the peripheral nervous system. It mainly causes mild, transient manifestations, but neurological complications may also occur. The main pathogenic mechanisms are direct cytophatic damage or indirect mechanisms resulting from an inflammatory response.


REFERENCES

  1. Carod-Artal FJ. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol. 2020 [acceso: 06/05/2020];70:311-22. Disponible en: Disponible en: https://www.neurologia.com/noticia/7687/complicaciones-neurologicas-por-coronavirus-y-covid-19

  2. Costa-Frossard França L, Meca-Lallana V, García-Domínguez JM. Documento EMCAM (Esclerosis Múltiple Comunidad Autónoma de Madrid) para el manejo de pacientes con esclerosis múltiple durante la pandemia de SARS-CoV-2. Rev Neurol. 2020[acceso: 06/05/2020];70:329-40. Disponible en: Disponible en: https://www.neurologia.com/articulo/2020155

  3. Abdullah JM, Wan Ismail WFN, Mohamad I, Ab Razak A, Harun A, Musa KI, et al. A Critical Appraisal of COVID-19 in Malaysia and Beyond. MJMS. 2020[acceso: 06/05/2020];27(2):1-9. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153689/

  4. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;27(2):1564-7. DOI: 10.1056/NEJMc2004973

  5. Butowt R, Bilinska K. SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection. ACS Chem Neurosci. 2020;11(9):1200-3. DOI: 10.1021/acschemneuro.0c00172

  6. Gilani S, Roditi R, Naraghi M. COVID-19 and anosmia in Tehran, Iran. Med Hypotheses. 2020;141(2):109757-68.

  7. Padrón-González AA, González-Losada C, Dorta Contreras A. Empleo del Reibergrama en manifestaciones neurológicas del dengue. Rev Haban Cienc Méd. 2017[acceso: 15/02/2020];16(5):711-9. Disponible en: Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/2004

  8. Rodriguez-Pérez JA, Pérez-Vallín V, Mirabal-Viel A, Padrón-González AA, Castillo-González W, González-Losada C et al. Epstein Barr Virus and Multiple Sclerosis. FASEB J. 2018;32(1):617-20. DOI: 10.1096/fasebj.2018.32.1_supplement.617.3

  9. Rodríguez-Pérez JA, Pérez-del-Vallín V, Mirabal-Viel A, González Losada C, Padron-Gonzalez AA, Castillo-González W et al. IgG antibody Index against Epstein Barr in Multiple Sclerosis patients. Frontiers Abstract Book. Ciudad de México: Ed Pelayo R; 2018. pp 422-7.

  10. González-Costa M, Padrón-González AA. Causality: autoimmunity and cáncer. Revista Cub de Investig Bioméd. 2019[acceso: 11/02/2020];38(1):1-4. Disponible en: Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/170/pdf

  11. Skinner D, Marro BS, Lane TE. Chemokine CXCL10 and Coronavirus-Induced Neurologic Disease. Viral Immunol. 2019[acceso: 16/05/2020];32(1):25-37. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30109979

  12. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020[acceso: 06/05/2020];1(2):357-63. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32240762/

  13. Matias-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu JA. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia. 2020[acceso: 06/05/2020];35(3):170-5. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32299636

  14. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020[acceso: 06/05/2020];20(2):3151-5. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167588/

  15. Bermejo-Valdés AJ, Cervera-Grau JM. Lighting Up Dark Areas of COVID-19. Ann Case Report 2020[acceso: 06/05/2020];14(2):394-9. Disponible en: Disponible en: https://www.gavinpublishers.com/articles/case-report-Annals-of-Case-Reports/lighting-up-dark-areas-of-covid-19

  16. Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. Mol Pharmacol. 2020[acceso: 06/05/2020];97(5):351-3. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32238438

  17. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. BMJ Open Diabetes Res Care. 2020[acceso: 06/05/2020];9(1):45-58. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32345362/

  18. Baig AM. Updates on What ACS Reported: Emerging Evidences of COVID-19 with Nervous System Involvement. ACS Chem Neurosci. 2020;24(1):176-90. DOI: 10.1021/acschemneuro.0c00181

  19. Das G, Mukherjee N. Neurological Insights of COVID-19 Pandemic. Brain Behav Immun Health. 2020[acceso: 06/05/2020];11(9):1206-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32320211/

  20. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020[acceso: 06/05/2020];11(7):995-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32167747/

  21. Desforges M, Le Coupanec A, Dubeau P. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses. 2019[acceso: 06/05/2020];12(1):14-23. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31861926

  22. Padrón-González AA, Dorta-Contreras AJ. Vía de las lectinas, una ruta del complemento en construcción. AAIC. 2018;49(1):5-12.

  23. Dorta-Contreras AJ, Padrón-González AA, C. González-Losada C, Lumpuy-Castillo J, Rodriguez-Pérez JA, Ramos-Robledo A, Martínez-Reyes J,Schmitz M, Zerr I, Gudmann Hansen A, Jensenius JC.MASP-3: A New Leptomeningeal Protein in the Lectin Pathway. FASEB J. 2018[acceso: 06/05/2020];32(1):1-3. Disponible en: Disponible en: https://www.fasebj.org/toc/fasebj/32/1_supplement

  24. Padrón González AA, Dorta Contreras AJ. Activación del complemento por la vía de las lectinas: rol en las enfermedades reumáticas. Rev Cuba Reumatol. 2017[acceso: 11/02/2020];19(1):231-4. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962017000400012&lng=es

  25. González-Losada C, Padrón-González AA, Lumpuy-Castillo J, Rodriguez-Pérez A, Castillo-González W, Dorta-Contreras AJ. Intrathecal Activation of the Lectin Pathway in Patients with Eosinophilic Meningitis by Angiostrongylus cantonensis. FASEB J. 2018;32(1):1-3. DOI: 10.1096/fasebj.2018.32.1_supplement.741.2

  26. Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. Epilepsia. 2020[acceso: 06/05/2020];127(1):436-6. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146675/

  27. Wheeler DL, Sariol A, Meyerholz DK, Perlman S. Microglia are required for protection against lethal coronavirus encephalitis in mice. J Clin Invest. 2018[acceso: 06/05/2020];128(3):931-43. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863772/

  28. González-Costa M, Padrón-González AA. La inflamación desde una perspectiva inmunológica: desafío a la Medicina en el siglo XXl. Rev Haban Cienc Méd. 2018[acceso: 15/02/2020];18(1):30-44. Disponible en: Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/2445

  29. Conde Cardona G, Quintana Pajaro LD, Quintero Marzola ID, Ramos Villegas Y, Moscote Salazar LR. Neurotropism of SARS-CoV 2: Mechanisms and manifestations. J Neurol Sci. 2020[acceso: 16/05/2020];412(1):116824. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141641/

  30. Zhou L, Liu HG. Early detection and disease assessment of patients with novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020[acceso: 16/05/2020];43(3):167-70. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32208917

  31. Tape C, Byrd KM, Aung S, Lonks JR, Flanigan TP, Rybak NR. COVID-19 in a Patient Presenting with Syncope and a Normal Chest X-ray. R I Med J. 2020;103(3):50-61

  32. Su L, Ma X. The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. BMJ. 2020[acceso: 16/05/2020];9(1):707-13. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32164079

  33. Tan X, Huang J, Zhao F, Zhou Y, Li JQ, Wang XY. Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha, China. Zhongguo dang dai er ke za zhi. 2020[acceso: 16/05/2020];22(4):294-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32312364

  34. Mishra N, Sellner P Taba S Öztürk R Helbok R . The need for neurologists in the care of COVID-19 patients. Neurology. 2020[acceso: 16/05/2020];2(1):1468-81. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32323891

  35. Coen M, Jeanson G, Alejandro Culebras Almeida L, Hubers A, Stierlin F, Najjar I, et al. Guillain-Barre Syndrome as a Complication of SARS-CoV-2 Infection. Brain Behav Immun. 2020[acceso: 16/05/2020];1591(20):30698. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32360440

  36. Shaikh AG, Mitoma H, Manto M. Cerebellar Scholars' Challenging Time in COVID-19 Pandemia. Cerebellum. 2020[acceso: 16/05/2020];19(3):343-4. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161715/

  37. Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun. 2020[acceso: 16/05/2020];14(4):349-50. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165103/

  38. Rodríguez Manso A, González-Costa M, Padrón-González AA. Hormones, food, stress and infections: their etiological role in autoimmune diseases. Rev Cubana Invest Bioméd. 2019[acceso: 07/04/2020];38(1):e164. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002019000100011&lng=es

  39. Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020[acceso: 07/04/2020];149(2):130-6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32196655

  40. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020[acceso: 06/05/2020];94:55-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32251791/

  41. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020[acceso: 06/05/2020];413(1):116832. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151535/

  42. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020[acceso: 06/05/2020];1591(20):30357-3. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/32240762

  43. Dorta-Contreras AJ, Bu-Coifiu Fanego R, Magraner-Tarrau ME, Montoro-Cardoso E, Núñez-Fernández FA, Fundora-Hernández H, et al. Neuroinmunología clínica. La Habana: Ed Academia; 2009. pp 79-85.




2020     |     www.medigraphic.com